<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154076</url>
  </required_header>
  <id_info>
    <org_study_id>E2090-S082-403</org_study_id>
    <nct_id>NCT00154076</nct_id>
  </id_info>
  <brief_title>A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of Zonisamide and Topiramate as Initial Monotherapy in
      Untreated Epilepsies
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>0, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients over 13 years old (complete the elementary school course).

          2. Patients had at least two seizures in the past and at least one seizure for the last 3
             months before screening.

          3. Patients had no antiepileptic drugs for the last 4 months.

          4. Women of childbearing age who agree to contraception during participating this
             clinical trial.

        Exclusion criteria:

          1. Pregnancy

          2. Patients who have progressive neurologic disease

          3. Allergy to sulfonamides

          4. Use of acetazolamide within a year

          5. Hemolytic anemia

          6. Patients who have abnormal liver function (GOT or GPT) values more than twice the
             normal values.

          7. Patients who have abnormal renal function (BUN or Creatinine) values more than three
             times the normal values.

          8. Patients who have history of drug or alcohol abuse.

          9. Glucose-6-phosphate dehydrogenase deficiency.

         10. Patients who were detected with renal stones on KUB (Kidney-Ureter-Bladder) test.

         11. Patients who have progressive internal or surgical disease.

         12. Patients who have progressive psychiatric disease.

         13. Patients who have mental retardation (IQ 70 and less).

         14. Patients taking Vit C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihee Mun</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Korea Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jihee Mun</name_title>
    <organization>Eisai Korea Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 21, 2010</submitted>
    <returned>August 17, 2010</returned>
    <submitted>June 20, 2012</submitted>
    <returned>July 25, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

